Vivoryon Therapeutics N.V.

0R3M.L

Biotechnology · Healthcare

Price

€1.13

-0.01 (-0.44%)

Market Cap

€33.3M

Exchange

London Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+34.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.0M (2021) → 27.0M (2025)

Vivoryon Therapeutics is a small biotech company based in the Netherlands that focuses on developing drugs to treat serious brain diseases. Its main area of research is Alzheimer's disease, where it works on blocking a specific enzyme called QPCT that is believed to help cause harmful protein buildup in the brain. The company does not sell any approved products yet — it is still in the clinical trial stage.

Vivoryon earns no product revenue right now. It funds its research through grants, partnerships, and by raising money from investors. The company operates primarily in Europe and runs clinical studies internationally. Its scientific focus on the QPCT enzyme gives it a specialized niche, but it faces the same major risk all early-stage biotechs do: clinical trials can fail, and the company must keep raising cash to survive. The key risk is whether its lead drug candidate can show strong enough results in trials to attract a larger partner or reach approval.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+47.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$4M/ year

↓ Declining (-69% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

20.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$2M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Vivoryon Therapeutics N.V. has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-208.0%

Weak — -208.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.04

Conservative — low debt load (0.04)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial